Table 1 Demographic and clinical characteristics: EOS count 100 to < 300 cells/mm3 by exacerbation history, mITT population
|  | BGF 320/14.4/10 µg | GFF 14.4/10 µg | BFF 320/10 µg |
|---|---|---|---|
EOS 100 to < 300 cells/mm3 – without exacerbation history in the preceding 12 months | N = 308 | N = 307 | N = 147 |
 Mean (SD) age, yearsa | 65.2 (7.9) | 64.9 (7.8) | 66.0 (7.1) |
 Sex, male n (%) | 207 (67.2) | 204 (66.4) | 110 (74.8) |
 EOS count |  |  |  |
  Median (range) cells per mm3 | 170.0 (100.0–295.0) | 165.0 (100.0–295.0) | 175.0 (100.0–295.0) |
  ≥ 150 cells/mm3, n (%) | 190 (61.7) | 188 (61.2) | 100 (68.0) |
 Current smoker, n (%) | 136 (44.2) | 129 (42.0) | 56 (38.1) |
 Mean (SD) number of pack-years smokedb | 56.6 (32.4) | 51.2 (27.0) | 51.4 (26.4) |
 Mean (SD) post-salbutamol FEV1, % predicted | 51.1 (13.8) | 51.6 (13.6) | 50.5 (13.5) |
 Moderate or severe COPD exacerbations in the past 12 months, n (%) |  |  |  |
  0 | 308 (100) | 307 (100) | 147 (100) |
  1 | 0 | 0 | 0 |
  ≥ 2 | 0 | 0 | 0 |
 Used ICS at screening, n (%) | 207 (67.2) | 206 (67.1) | 102 (69.4) |
 COPD severity, n (%) |  |  |  |
  Mild | 0 | 0 | 1 (0.7) |
  Moderate | 157 (51.0) | 166 (54.1) | 70 (47.6) |
  Severe | 131 (42.5) | 121 (39.4) | 70 (47.6) |
  Very severe | 20 (6.5) | 20 (6.5) | 6 (4.1) |
 Mean (SD) total CAT scorec | 18.7 (6.6) | 18.3 (6.2) | 18.6 (6.8) |
 Reversibilityd, n (%) | 137 (44.5) | 136 (44.3) | 66 (44.9) |
EOS 100 to < 300 cells/mm3– with exacerbation history in the preceding 12 months | N = 102 | N = 92 | N = 45 |
   Mean (SD) age, yearsa | 62.9 (8.7) | 64.8 (8.0) | 62.8 (7.2) |
   Sex, n (%) male | 67 (65.7) | 56 (60.9) | 26 (57.8) |
   EOS count |  |  |  |
      Median (range) cells per mm3 | 165.8 (100.0–295.0) | 165.0 (105.0–295.0) | 150.0 (100.0–290.0) |
      ≥ 150 cells/mm3, n (%) | 63 (61.8) | 61 (66.3) | 23 (51.1) |
   Current smoker, n (%) | 42 (41.2) | 39 (42.4) | 21 (46.7) |
   Mean (SD) number of pack-years smokedb | 48.5 (25.7) | 49.8 (25.8) | 56.0 (36.0) |
   Mean (SD) post-salbutamol FEV1, % predicted | 49.3 (13.2) | 47.7 (14.3) | 49.1 (16.1) |
   Moderate or severe COPD exacerbations in the past 12 months, n (%) |  |  |  |
      0 | 0 | 0 | 0 |
      1 | 77 (75.5) | 67 (72.8) | 34 (75.6) |
      ≥ 2 | 25 (24.5) | 25 (27.2) | 11 (24.4) |
   Used ICS at screening, n (%) | 76 (74.5) | 67 (72.8) | 36 (80.0) |
   COPD severity, n (%) |  |  |  |
      Mild | 1 (1.0) | 0 | 0 |
      Moderate | 44 (43.1) | 38 (41.3) | 20 (44.4) |
      Severe | 51 (50.0) | 42 (45.7) | 19 (42.2) |
      Very severe | 6 (5.9) | 12 (13.0) | 6 (13.3) |
   Mean (SD) total CAT scorec | 19.5 (6.3) | 18.5 (6.5) | 19.3 (6.2) |
   Reversibilityd, n (%) | 50 (49.0) | 26 (28.3) | 20 (44.4) |